This analysis of data from the largest provider of health care in the United Kingdom highlights the significant burden of TRD on both patients and providers.
• Major Depressive Disorder (MDD) is a globally prevalent chronic mood disorder with a significant disease burden. The Global Burden of Disease 2013 study estimated the global prevalence to be 25.3 million cases in 2013.1 It was ranked second in the list of the 25 leading causes of years lived with disability (YLD) with a mean of 51.8 million YLDs, which represented a 53% increase from 1990, when it was ranked third. • The clinical and economic burden of TRD is significantly higher than of MDD.
› Prevalence of comorbidities including anxiety disorders, chronic pain, and fibromyalgia was significantly higher in patients with likely TRD (20.5%, 23.2%, and 6.4%, respectively) than in non-TRD patients (12.6%, 14.5%, and 3.0%, respectively).
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› Costs of medical services associated with TRD have been reported to be more than twice those associated with MDD ($10,954 vs $5,025).
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› Patients with TRD have been found to be twice as likely as those with MDD to be hospitalized, with health care costs for hospitalized TRD patients being 6-fold higher than for non-TRD patients.
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• We analyzed the use of antidepressants (AD) during TRD and non-TRD episodes among MDD patients in the UK Clinical Practice Research Datalink (CPRD) between 2000 and 2012.
• Of the 427,467 unique MDD patients for whom data were available, 136,079 (31.8%) were retained, while 291,388 (68.2%) were excluded because they lacked an index diagnosis, met an exclusion diagnosis criterion, did not meet age criteria, or had missing age or gender information (Table 1) . • While TRD episodes lasted more than three years on average, non-TRD drug treated episodes lasted only one year (Table 3 ). The mean duration of a TRD episode was 1,239 days versus only 305 days in the case of non-TRD episodes.
• The duration of a LOT in TRD episodes was lower than for drug-treated non-TRD episodes, suggesting more frequent changes of regimens (Table 4 ).
• Use of combination drug regimens was seen in 46.6% of TRD episodes compared with 12.8% of drug-treated non-TRD episodes (P<0.05).
• A greater proportion of TRD patients suffered from co-morbidities than did non-TRD patients (P<0.05 in each case below):
» Anxiety and panic disorder: 50.0% vs 32.7% of TRD and non-TRD patients, respectively.
» Fatigue: 9.0% vs 5.4% of TRD and non-TRD patients, respectively. » Weight loss: 7.6% vs 4.7% of TRD and non-TRD patients, respectively. » Sexual dysfunction: 5.3% vs 3.4% of TRD and non-TRD patients, respectively. » Suicide: 6.3% vs 3.3% of TRD and non-TRD patients, respectively. » Epilepsy: 3.1% vs 1.5% of TRD and non-TRD patients, respectively.
» Drug/substance abuse: 0.3% vs 0.1% of TRD and non-TRD patients, respectively.
• Patients experiencing TRD episodes underwent 4 times as many sessions of psychotherapy/ cognitive behavioral therapy per episode than those experiencing non-TRD episodes (mean number of sessions: 0.047 in TRD episodes vs 0.011 in non-TRD episodes; ratio: 4.3) (P<0.05).
• A greater proportion of patients with at least one TRD episode (17 patients; 0.273%) underwent electroconvulsive therapy than did non-TRD patients (23 patients; 0.023%) (P<0.05).
• Psychiatrist visits by patients with TRD were more than five times higher than those by non-TRD patients (mean number of visits per TRD episode was 0.54 vs 0.10 per non-TRD episode with at least one ADAP prescription) (P<0.05). This was attributable partly to the longer duration of TRD episodes and partly to the higher rate of visits.
• While almost half (46%) of all TRD episodes had up to four LOTs, less than a fifth (19%) of non-TRD episodes with one or more ADAP prescriptions had more than one LOT (Figure 2 ).
• One in 20 (6,311 [5.15%]) distinct MDD episodes with one or more ADAP prescription were treatment-resistant, with 6,221 (5.9%) of all MDD patients experiencing at least one TRD episode (Table 2 ).
• More than 50% of TRD episodes became so within one year after the start of the episode (Figure 1 ). The median time to development of TRD was <11 months (307 days; range 174-412 days), while the mean time to development of TRD was 503 days.
STUDY POPULATION
• Adults, aged between 18 and 65 years, with an MDD diagnosis were considered for the analysis. Patients were excluded if:
» They had an exclusion diagnosis during the evaluation period (detailed list of exclusion and inclusion diagnoses ICD-9 codes is available from the authors upon request).
» An index diagnosis date could not be found -ie, if one of the two following conditions was not met for any MDD diagnosis claim:
› 120-day clear history with no AD prescription and other inclusion diagnosis.
› Continuous eligibility for the 28-month period starting 4 months prior to the diagnosis date.
• Information on age or gender was missing.
STUDY DESIGN
• Business rules centered on diagnoses and on use of antidepressants were used to identify new MDD episodes and to define TRD.
• An MDD episode was defined as an episode commencing on an index diagnosis date and ending 120 days after the last diagnosis date or AD prescription claim.
» An index diagnosis date was one that was not preceded by any inclusion diagnosis or an AD prescription claim in the preceding 120 days.
» A patient may have had multiple index diagnoses dates, and thus may have had multiple new episodes.
• The definition of treatment-resistant depression was governed by the following rules:
» All distinct regimens in an episode were deemed failures, except:
› the very last regimen of the episode.
› if any regimen had an immediately succeeding step-down regimen (ie, one or more of the products were discontinued while no other product was added), assuming this was applicable to all the instances in which the regimen appeared.
» If there were two or more distinct failed regimens in an episode, the entire episode was categorized as a TRD episode.
» In this context, a regimen was defined as the combination of anti-depressant and anti-psychotic/anti-manic (ADAP) drugs that were concurrently valid at a given time. The list of ADAP drugs used for this purpose is available from the authors upon request.
• A regimen/line of treatment (LOT) was governed by the following rule:
» Non-ADAP drugs were not considered when determining regimens/LOTs, not only for the purpose of categorizing episodes as TRD but also for duration or switch analysis.
• Additional business rules relating to grace periods for drugs and regimens were applied in defining a TRD patient.
• The difference of proportions test was used, at a significance level of 5%, to compare the proportion of TRD and non-TRD patients suffering from comorbidities as well as the proportions that required use of resources such as psychotherapy sessions or psychiatrist visits. 
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